Pharmaceutical Administration and Regulations in Japan - Nihs
Pharmaceutical Administration and Regulations in Japan - Nihs
Pharmaceutical Administration and Regulations in Japan - Nihs
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
3.16 Adverse Drug Reaction (ADR) <strong>and</strong><br />
Infection Report<strong>in</strong>g<br />
When marketers of drugs are <strong>in</strong>formed of<br />
any adverse reactions, <strong>in</strong>fections, etc. as<br />
specified by MHLW ord<strong>in</strong>ance for trial<br />
products or their marketed products, they<br />
must report them to the M<strong>in</strong>ister with<strong>in</strong> the<br />
specified period (Notification No. 0317006<br />
dated March 17, 2005).<br />
As of December 28, 1999, the use of the<br />
<strong>Japan</strong>ese version of ICH MedDRA<br />
(MedDRA/J) was authorized for report<strong>in</strong>g of<br />
adverse drug reactions <strong>and</strong> <strong>in</strong>fectious<br />
diseases <strong>and</strong> its use was enforced on April 1,<br />
2004 (Notification No. 0325001 of the Safety<br />
Division <strong>and</strong> Notification No. 0325032 of the<br />
Evaluation <strong>and</strong> Licens<strong>in</strong>g Division, PMSB<br />
dated March 25, 2004).<br />
S<strong>in</strong>ce October 27, 2003, electronic<br />
adverse drug reaction reports have been<br />
accepted (Notification No. 0828010 of the<br />
Safety Division dated August 28, 2003. Refer<br />
to the follow<strong>in</strong>g site). The reports are<br />
required to be sent to the PMDA from April 1,<br />
2006 (Partial Modification of the<br />
<strong>Pharmaceutical</strong> Affairs Law In accordance<br />
with the Special Corporation Rationalization<br />
Plan dated March 25, 2004).<br />
The f<strong>in</strong>al report of the “Study group on<br />
identification <strong>and</strong> prevention of recurrences<br />
of drug-<strong>in</strong>duced hepatitis” published <strong>in</strong> March<br />
2010 discusses problems <strong>and</strong> future<br />
<strong>Pharmaceutical</strong> <strong>Regulations</strong> <strong>in</strong> <strong>Japan</strong>:<br />
prospects related to the drug adverse event<br />
report<strong>in</strong>g system, pharmacovigilance<br />
programs, <strong>and</strong> the problems of off-label drug<br />
use <strong>and</strong> use of unapproved drugs.<br />
http://www.mhlw.go.jp/sh<strong>in</strong>gi/2010/03/s03<br />
00-1.html<br />
3.17 Dissem<strong>in</strong>ation of Information<br />
Marketers of drugs or medical devices,<br />
wholesalers, marketers or leasers of medical<br />
devices, <strong>and</strong> overseas restrictive approval<br />
holders are asked collect <strong>and</strong> exam<strong>in</strong>e<br />
<strong>in</strong>formation on efficacy, safety, <strong>and</strong> proper<br />
use of drugs <strong>and</strong> medical devices <strong>and</strong> supply<br />
such <strong>in</strong>formation to health professionals such<br />
as physicians <strong>and</strong> pharmacists.<br />
3.18 Measures related to the Law<br />
Concern<strong>in</strong>g Access to Information<br />
Held by Adm<strong>in</strong>istrative Organizations<br />
With the enactment of the Law<br />
Concern<strong>in</strong>g Access to Information Held by<br />
Adm<strong>in</strong>istrative Organizations on April 1,<br />
2000, anyone has the right to request<br />
disclosure of documents reta<strong>in</strong>ed by national<br />
government organizations. This law covers<br />
disclosure of documents reta<strong>in</strong>ed by<br />
government organizations except those<br />
concern<strong>in</strong>g non-disclosable <strong>in</strong>formation such<br />
as <strong>in</strong>formation on <strong>in</strong>dividuals, <strong>in</strong>formation on<br />
corporations, etc. This was partially<br />
amended by Cab<strong>in</strong>et Order No. 371,<br />
2011-3 - 33 -